Steven Seedhouse
Stock Analyst at Raymond James
(3.21)
# 1,028
Out of 4,876 analysts
172
Total ratings
42.51%
Success rate
2.31%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $73 → $77 | $50.52 | +52.41% | 19 | May 13, 2025 | |
| KRRO Korro Bio | Initiates: Overweight | $74 | $12.34 | +499.68% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.03 | +42.25% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $17.44 | +60.55% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $5.44 | +763.97% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.83 | +1,101.06% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $9.66 | +107.04% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $28.17 | +269.19% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.55 | +1,319.35% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $18.13 | +208.88% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $9.95 | +392.46% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.16 | +548.15% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $107.62 | -13.58% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $23.29 | +191.97% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $18.40 | +476.09% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $3.69 | +307.06% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $10.05 | +457.21% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.28 | +6,156.70% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $9.61 | +493.13% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.15 | +1,813.04% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.12 | +701.89% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $2.59 | +1,251.35% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $45.71 | -16.87% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $29.83 | +138.02% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.30 | +284.62% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $23.38 | +62.53% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $14.41 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.79 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $16.90 | +1,497.63% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $126.92 | - | 2 | Apr 23, 2020 |
Mirum Pharmaceuticals
May 13, 2025
Maintains: Strong Buy
Price Target: $73 → $77
Current: $50.52
Upside: +52.41%
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $12.34
Upside: +499.68%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.03
Upside: +42.25%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $17.44
Upside: +60.55%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $5.44
Upside: +763.97%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.83
Upside: +1,101.06%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $9.66
Upside: +107.04%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $28.17
Upside: +269.19%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.55
Upside: +1,319.35%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $18.13
Upside: +208.88%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $9.95
Upside: +392.46%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.16
Upside: +548.15%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $107.62
Upside: -13.58%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $23.29
Upside: +191.97%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $18.40
Upside: +476.09%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $3.69
Upside: +307.06%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $10.05
Upside: +457.21%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.28
Upside: +6,156.70%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $9.61
Upside: +493.13%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.15
Upside: +1,813.04%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.12
Upside: +701.89%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $2.59
Upside: +1,251.35%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $45.71
Upside: -16.87%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $29.83
Upside: +138.02%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.30
Upside: +284.62%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $23.38
Upside: +62.53%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $14.41
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.79
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $16.90
Upside: +1,497.63%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $126.92
Upside: -